Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 8/20 | 0.33 |
| ▸ | PRCP | P42785 | 2/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 3/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18501430 | 0.89 | SCN10A (0.33) | SSTR3KCNH2SSTR5TTKPRCP | |
| SCHEMBL16577379 | 0.87 | SCN10A (0.34) | SSTR3KCNH2SSTR5TTKPRCP | |
| SCHEMBL18501409 | 0.86 | SCN10A (0.34) | SSTR3KCNH2SSTR5TTKPRCP | |
| SCHEMBL18501424 | 0.86 | SCN10A (0.34) | SSTR3KCNH2SSTR5TTKPRCP | |
| SCHEMBL16577540 | 0.85 | SCN10A (0.39) | SSTR3KCNH2SSTR5TTKPRCP | |
| SCHEMBL16577433 | 0.81 | SCN10A (0.41) | SSTR3KCNH2SSTR5TTKPRCP | |
| SCHEMBL16577490 | 0.80 | PRCP (0.32) | SSTR3KCNH2TTKPRCPSCN10A | |
| SCHEMBL16577477 | 0.78 | PRCP (0.35) | PRCPSCN10A | |
| SCHEMBL18501422 | 0.78 | SCN10A (0.35) | SSTR3KCNH2SSTR5TTKSCN10A | |
| SCHEMBL18501436 | 0.76 | SSTR3 (0.33) | SSTR3KCNH2PRCPSCN10AMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738629-B2 | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-08-22 | — | — | US | disclosed |
| US-20170044140-A1 | BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044140-A1 | BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SLC10A1, CYP7A1, CYP3A43 | SSTR3 3971/4885KCNH2 3621/4885SSTR5 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.